



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2015/10/07	(51) Cl.Int./Int.Cl. <i>A61K 39/395</i> (2006.01), <i>A61K 45/06</i> (2006.01)
(87) Date publication PCT/PCT Publication Date: 2016/04/14	
(85) Entrée phase nationale/National Entry: 2018/02/09	(71) Demandeur/Applicant: KADMON CORPORATION, LLC, US
(86) N° demande PCT/PCT Application No.: US 2015/054569	(72) Inventeurs/Inventors: LU, DAN, US; ZHU, ZHENPING, US
(87) N° publication PCT/PCT Publication No.: 2016/057726	
(30) Priorité/Priority: 2014/10/07 (US62/061,097)	(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : ANTICORPS HUMAINS ANTI-VEGFR-2/KDR
(54) Title: HUMAN ANTI-VEGFR-2/KDR ANTIBODIES

Kabat No.	1	2	3	4
SEQ ID NO.	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	6 7 8 9 0 1 2 3 4 5	6 7 8 9 0 1 2 3 4 5 A B	6 7 8 9 0 1 2 3
4	E V Q L L E S G G G L V Q P G G S L R L S C A A S	G F T F S W Y V M G - -	W V R Q A P G K	
12	E V Q L L E S G G G L V Q P G G S L R L S C A A S	G F T F S W Y I M L - -	W V R Q A P G K	

Kabat No.	5	6	7	8
SEQ ID NO.	4 5 6 7 8 9	0 1 2 A B C 3 4 5 6 7 8 9 0 1 2 3 4 5	6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 A B C	
4	G L E W V S	S I Y P - - S G G A T N Y A D S V K G	R F T I S R D N S K N T L Y L Q M N S L	
12	G L E W V S	S I G S - - S G G F T D Y A D S V K G	R F T I S R D N S K N T L Y L Q M N S L	

Kabat No.	9	10	1
SEQ ID NO.	3 4 5 6 7 8 9 0 1 2 3 4	5 6 7 8 9 0 A B C D E F G H I J K 1 2	3 4 5 6 7 8 9 0 1 2 3
4	R A E D T A V Y Y C A R	G N Y F - - - - - D Y	W G Q G T L V T V S S
12	R A E D T A V Y Y C A R	G L A A P - - - - - R S	W G R G T L V T V S S

Fig.1A

(57) **Abrégé/Abstract:**
The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 45/06 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2015/054569

(22) International Filing Date:
7 October 2015 (07.10.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/061,097 7 October 2014 (07.10.2014) US

(71) Applicant: KADMON CORPORATION, LLC [US/US];
450 East 29th Street, New York, NY 10016 (US).

(72) Inventors: LU, Dan; 24 Olde Woods Lane, Montvale, NJ
07645 (US). ZHU, Zhenping; 19 Mulholland Drive,
Woodcliff Lake, NJ 07677 (US).

(74) Agents: SOMERIVILLE, Deborah A. et al.; Kenyon &
Kenyon LLP, One Broadway, New York, NY 10004
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:
— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
1 September 2016

(54) Title: HUMAN ANTI-VEGFR-2/KDR ANTIBODIES

Kabat No.	1	2	3	4
SEQ ID NO.	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 A B	6 7 8 9 0 1 2 3 4 5	6 7 8 9 0 1 2 3 4 5 A B	6 7 8 9 0 1 2 3
4	E V Q L L E S G G G L V Q P G G S L R L S C A A S	G F T F S W Y V M G - -	W V R Q A P G K	
12	E V Q L L E S G G G L V Q P G G S L R L S C A A S	G F T F S W Y I M L - -	W V R Q A P G K	

Kabat No.	5	6	7	8
SEQ ID NO.	4 5 6 7 8 9 0 1 2 A B C 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 A B C	6 7 8 9 0 1 2 3 4 5	6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 A B C	
4	G L E W V S	S I Y F - - S G G A T N Y A D S V K G	R F T I S R D N S K N T L Y L Q M N S L	
12	G L E W V S	S I G S - - S G G F T D Y A D S V K G	R F T I S R D N S K N T L Y L Q M N S L	

Kabat No.	9	10	11
SEQ ID NO.	3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 A B C D E F G H I J K L 1 2 3 4 5 6 7 8 9 0 1 2 3	5 6 7 8 9 0 A B C D E F G H I J K L 1 2	3 4 5 6 7 8 9 0 1 2 3
4	R A E D T A V Y Y C A R	G N Y F - - - - - D Y	W G Q G T L V T V S S
12	R A E D T A V Y Y C A R	G L A A P - - - - - R S	W G R G T L V T V S S

(57) Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

HUMAN ANTI-VEGFR-2/KDR ANTIBODIES

FIELD OF THE INVENTION

[0001] The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases and hyperproliferative disorders, and can be used alone or in combination with other agents.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application No. 62/061,097, filed on October 7, 2014, which is incorporated herein by reference in its entirety. This application also relates to PCT/US2013/063754, filed October 7, 2013, and to U.S. Ser. No. 61/710,420, filed October 5, 2012, both of which are incorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION

[0002] Angiogenesis is a highly complex process of developing new blood vessels that involves the proliferation and migration of, and tissue infiltration by capillary endothelial cells from pre-existing blood vessels, cell assembly into tubular structures, joining of newly forming tubular assemblies to closed-circuit vascular systems, and maturation of newly formed capillary vessels.

[0003] Angiogenesis is important in normal physiological processes including embryonic development, follicular growth, and wound healing. Undue angiogenesis also leads to neovascularization in neoplastic diseases, and in non-neoplastic diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and neovascular glaucoma. Anti-angiogenic therapy that targets vascular endothelial growth factor (VEGF) with ranibizumab (Lucentis[®]) has been shown to be effective in delaying progression of AMD. However, neovascularization is complex and multiple angiogenic mechanisms are likely to contribute. There remains a need to develop agents and therapies for treating diseases associated with neovascularization.

SUMMARY OF THE INVENTION

[0004] The present invention provides human antibodies, and fragments thereof that bind to VEGFR-2 (KDR). In some embodiments, the antibodies block ligand binding (e.g., one or more of VEGF-A, VEGF-C, VEGF-D, or VEGF-E) to VEGFR-2. In some

embodiments, the antibodies neutralize activation of VEGFR-2. The antibodies are used for treating neoplastic diseases, including, for example, solid and non-solid tumors, and hyperproliferative disorders. Accordingly, the invention provides methods of neutralizing the activation of KDR, methods of inhibiting tumor growth, including inhibition of tumor associated angiogenesis, and methods of treating angiogenesis related disorders. The present invention provides kits having human antibodies or antibody fragments that bind to VEGFR receptors.

[0005] In one embodiment, the invention provides an isolated antibody or fragment thereof that binds to human VEGFR2, comprising a heavy chain variable domain, which comprises a CDR1, a CDR2, and a CDR3 sequence, wherein:

(i) the CDR1 sequence is GFTFSWYVMG (SEQ ID NO: 237),

(ii) the CDR2 sequence is selected from the group consisting of

SIYPQGGATSYADSVKG (SEQ ID NO: 238),

SIYPQGGATNYADSVKG (SEQ ID NO: 239), and

SIYPSGGATNYADSVKG (SEQ ID NO: 240); and

(ii) the CDR3 sequence selected from the group consisting of

GNYFDY (SEQ ID NO: 241),

GNYLDY (SEQ ID NO: 242),

GPYLDY (SEQ ID NO: 243) and

GSYLDY (SEQ ID NO: 244),

with the proviso that the heavy chain variable domain does not comprise both the CDR2 sequence of SEQ ID NO: 240 and the CDR3 sequence of SEQ ID NO: 241.

[0001] In one embodiment, the invention provides an isolated antibody or fragment thereof that binds to human VEGFR2, comprising a light chain variable domain, which comprises a CDR1, a CDR2, and a CDR3 sequence, wherein

(i) the CDR1 sequence is RASQSVSSNYFG (SEQ ID NO: 245),

(ii) the CDR2 sequence is GASSRAT (SEQ ID NO: 246), and

(iii) the CDR3 sequence is selected from the group consisting of

QQFDSLPLT (SEQ ID NO: 247),

QQHDSSPLS (SEQ ID NO: 248),
 QQFDSSPLS (SEQ ID NO: 249), and
 QQFDSSPLT (SEQ ID NO: 250).

[0001] In one embodiment of the invention, the CDR2 of the heavy chain variable domain has the sequence SIYPQGGATSYADSVKG (SEQ ID NO: 238), and the CDR3 of the heavy chain variable domain has the sequence GNYFDY (SEQ ID NO: 241).

[0002] In one embodiment of the invention, the CDR3 of the light chain variable domain has the sequence QQFDSLPLT (SEQ ID NO: 247).

[0003] In one embodiment of the invention, the heavy chain variable domain has a sequence that is selected from the group consisting of
 EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPQGG
 ATSYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGNYFDYWGQGTLV
 TVSS (SEQ ID NO: 200),

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMSWVRQAPGKGLEWVSSIYPQGG
 ATNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGNYFDYWGQGTLV
 TVSS (SEQ ID NO: 208),

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPSGG
 ATNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGNYLDYWGQGTLV
 TVSS (SEQ ID NO: 216),

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPSGG
 ATNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGPYLDYWGQGTLV
 TVSS (SEQ ID NO: 224), and

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPSGG
 ATNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGSYLDYWGQGTLV
 TVSS (SEQ ID NO: 232).

[0004] In one embodiment of the invention, the light chain variable domain has a sequence that is selected from the group consisting of
 DIQMTQSPGTLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
 GIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQFDSLPLTFGGGGTKVEIKR (SEQ ID
 NO: 204),

DIQMTQSPGTLSSLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
GIPDRFSGSGSGTDFTLTISRLEP EDSAVYYCQQHDSSPLSFGGGGTKVEIKR (SEQ ID
NO: 212),

DIQMTQSPGTLSSLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
GIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQFDSSPLSFGGGGTKVEIKR (SEQ ID
NO: 220),

DIQMTQSPGTLSSLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
GIPDRFSGSGSGTDFTLTISRLEP EDSAVYYCQQFDSSPLTFGGGGTKVEIKR (SEQ ID
NO: 228), and

DIQMTQSPGTLSSLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
GIPDRFSGSGSGTDFTLTISRLEP EDSAVYYCQQFDSSPLTFGGGGTKVEIKR (SEQ ID
NO: 236).

[0005] In one embodiment of the invention, the heavy chain variable domain has a sequence that is

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPQGG
ATSYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGNYFDYWGQGTLV
TVSS (SEQ ID NO: 200), and the light chain variable domain has a sequence that is
DIQMTQSPGTLSSLSPGEGATLSCRASQSVSSNYFGWYQQKPGQAPRLLIYGASSRAT
GIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQFD SLP LTFGGGGTKVEIKR (SEQ ID
NO: 204).

[0006] In one embodiment of the invention, the antibody or fragment has isotype IgG.

[0007] In one embodiment of the invention, the antibody or fragment is an scFv, Fv, Fab', Fab, F(ab')₂, or diabody.

[0008] In one embodiment of the invention, the the antibody or fragment binds to human VEGFR2 and murine hVEGFR2.

[0009] The present invention provides an isolated nucleic acid encoding the antibody or fragment of the present invention.

[0010] The present invention provides a nucleic acid vector comprising an isolated nucleic acid encoding the antibody or fragment of the present invention.

[0011] The present invention provides a prokaryotic or eukaryotic host cell comprising an isolated nucleic acid encoding the antibody or fragment of the present invention.

[0012] The present invention provides a composition comprising an antibody or fragment of the present invention, and a pharmaceutically acceptable carrier.

[0013] The present invention provides a method of neutralizing activation of human VEGFR2 or murine VEGFR2 comprising contacting a cell with an effective amount of an antibody or fragment of the present invention.

[0014] The present invention provides a method of inhibiting angiogenesis comprising administering to a subject an effective amount of an antibody or fragment of the present invention.

[0015] The present invention provides a method of reducing tumor growth comprising administering to a subject an effective amount of an antibody or fragment of the present invention.

[0016] The present invention provides a method of treating a neoplastic diseases in a subject, comprising administering to a subject an effective amount of an antibody or fragment of the present invention, wherein the neoplastic diseases is selected from the group consisting of lung cancer, colorectal cancer renal cell carcinoma, glioblastoma, ovarian cancer, bladder cancer, gastric cancer, multiple myeloma, non-small cell lung cancer and pancreatic cancer.

[0017] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of an epidermal growth factor receptor (EGFR) antagonist.

[0018] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of an fms-like tyrosine kinase receptor (fl t-1) antagonist.

[0019] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of a rho associated kinase 2 (ROCK2) antagonist.

[0020] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of a matrix metalloproteinase antagonist.

[0021] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of a PDGFR β antibody.

[0022] In one embodiment of the invention, the method which further comprises administering to a subject an effective amount of a PD-L1 antibody.

[0023] In one embodiment of the invention, the patient is a human..

BRIEF DESCRIPTION OF THE FIGURES

[0024] Figures 1A-C show human heavy chain, lambda light chain, and kappa light chain variable region sequences, respectively, of anti-VEGFR2 antibodies of the invention identified by phage display.

[0025] Figure 2 shows binding of antibodies of the invention to hVEGFR2 (top) and a construct containing domains 2 and 3 of hVEGFR2 (middle). The bottom panel shows ligand (VEGF₁₆₅) blocking.

[0026] Figure 3 shows Mabs 101 and 102 of the invention inhibit VEGFA-stimulated phosphorylation of VEGFR2, AKT, and MAPK in porcine aortic endothelial (PAE) cells overexpressing KDR (human VEGFR2).

[0027] Figure 4 shows binding to hVEGFR2 and VEGF₁₆₅ ligand blocking by Mabs 104, 105, 106, and 108. Similar results were obtained for Mabs 103, 107, 109, and 110 in a separate experiment. These Mabs contain the heavy chain variable domain of Mab101, recombined with different light chain variable domains.

[0028] Figure 5 shows Mabs 105 and 106 of the invention inhibit VEGFA-stimulated phosphorylation of VEGFR2, AKT, and MAPK in porcine aortic endothelial (PAE) cells overexpressing KDR (human VEGFR2).

[0029] Figure 6A depicts heavy chain amino acid sequences of five affinity matured antibodies derived from Mab 138, which contains the V_H domain having SEQ ID NO:4 (sequence also shown in this Figure). Figure 6B depicts light chain amino acid sequences of the same five affinity matured antibodies derived from SEQ ID NO:160 (sequence also shown in this Figure).

[0030] Figure 7A depicts binding of antibodies of the invention to soluble human and murine VEGFR2 compared to DC101 (a murine monoclonal Ab that binds to murine VEGFR2) and a control antibody that binds only to human VEGFR2. Mab 147 binds to both

human and murine VEGFR2. Mab 106 binds to human VEGFR2 but not murine VEGFR2. Figure 7B depicts data from ligand blocking experiments. Mab 147 blocks the binding of human VEGF with human VEGFR2 and the binding of murine VEGF with murine VEGFR2. Mab 106 blocks the binding of human VEGF with human VEGFR2 but not the binding of murine VEGF with murine VEGFR2.

[0031] Figure 8A depicts the binding of Mab106 and Mab 147 to human VEGFR2 on HUVEC (Human Umbilical Vein Endothelial Cells) and porcine aortic endothelial (PAE) cells overexpressing KDR (KDR-PAE). Figure 8B show Mab 147, but not Mab 106, binds to VEGFR2 on MS1 murine endothelial cells. In Fig. 8A and 8B, the control is an antibody that binds to hVEGFR2 but not mVEGFR2.

[0032] Figure 9 shows inhibition of VEGFR2-mediated signal transduction by Mab 106 and Mab 147. Mab 106 and Mab 147 inhibit phosphorylation of KDR and p44/42 in KDR-PAE (Fig. 9A) cells and in HUVEC (Fig. 9B) in a dose dependent manner.

[0033] Figure 10A depicts inhibition of proliferation of KDR-PAE cells by Mab 106, Mab 147, and a control antibody that binds to hVEGFR2. Figure 10B shows inhibition of induced cell migration. Migration of KDR-PAE cells was induced with a VEGF gradient (50 ng/ml VEGF (up), 100 ng/ml VEGF (low)). The plot depicts cell counts in the presence of 0.6 µg/ml, 3 µg/ml, or 15 µg/ml of Mab 106 or Mab 147 antibody.

[0034] Figure 11 depicts inhibition of VEGF-induced migration of KDR-PAE cells by Mab 147.

[0035] Figure 12A depicts inhibition of VEGFR2-mediated signal transduction in murine EOMA cells by Mab 147. And Figure 12B depicts FACS studies demonstrating that Mab 147 has increased binding to EOMA cells by comparison to control antibodies.

DETAILED DESCRIPTION

[0036] In one aspect, the invention provides novel VEGFR2 antibodies or antigen binding fragments of such antibodies are employed, which are effective to inhibit VEGFR2-dependent signal transduction. As used herein, “inhibiting a receptor” means diminishing and/or inactivating the intrinsic kinase activity of the receptor to transduce a signal. A reliable assay for VEGFR2 inhibition is reduction of receptor phosphorylation.

[0037] The present invention is not limited by any particular mechanism of VEGFR2 inhibition. The mechanism followed by one antibody is not necessarily the same as that

followed by another. Some possible mechanisms include preventing binding of the VEGF ligand to the extracellular binding domain of the VEGFR2, and preventing dimerization or oligomerization of receptors. Other mechanisms cannot, however, be ruled out.

[0038] Antibodies are proteins that recognize and bind to a specific antigen or substance. In preferred embodiments, the antibodies of the present invention bind KDR at least as strongly as the natural ligand. Affinity, represented by the equilibrium constant for the dissociation of an antigen with an antibody (K_d), measures the binding strength between an antigenic determinant and an antibody binding site. Avidity is the measure of the strength of binding between an antibody with its antigen. Avidity is related to both the affinity between an antigenic determinant and an antigen binding site on the antibody, and the number of binding sites (valence) per antibody. For example, a monovalent antibody (e.g., Fab) has one binding site for a particular epitope. An IgG antibody has two antigen binding sites. Typical values of K (the reciprocal of the dissociation constant K_d) are 10^5 to 10^{11} liters/mol. Any K weaker than 10^4 liters/mol is considered to indicate binding which is nonspecific.

[0039] Antibodies of the invention inhibit activation of VEGFR2. One measure of VEGFR2 inhibition is reduced tyrosine kinase activity of the receptor. Tyrosine kinase inhibition can be determined using well-known methods, such as measuring the autophosphorylation level of the receptor. Inhibition of VEGFR2 can also be observed through inhibition or regulation of phosphorylation events of natural or synthetic VEGFR2 substrates and other components of the VEGFR2 signal transduction pathway. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., *J. Pharmacol. Exp. Ther.*, 283: 1433-44 (1997) and Batley et al., *Life Sci.*, 62: 143-50 (1998).

[0040] *In vivo* assays can also be utilized. For example, receptor tyrosine kinase inhibition can be observed by mitogenic assays using cell lines stimulated with receptor ligand in the presence and absence of inhibitor. For example, HUVEC cells (ATCC) stimulated with VEGF can be used to assay VEGFR inhibition. Another method involves testing for inhibition of growth of VEGF-expressing tumor cells, using for example, human tumor cells injected into a mouse. See, U.S. Patent No. 6,365,157 (Rockwell et al.).

[0041] The invention provides anti-VEGFR2 antibodies, including nucleic acids encoding such antibodies and compositions comprising such antibodies. In one embodiment the invention provides an isolated antibody heavy chain variable region comprising a CDR-1H, CDR-2H, and CDR-3H sequence, wherein:

(i) the CDR-1H sequence is GFTFSWYX₁MX₂ (SEQ ID NO:185), wherein X₁ is V or I, X₂ is G or L,

(ii) the CDR-2H sequence is SIX₁X₂SGGX₃TX₄YADSVKG (SEQ ID NO:186), wherein X₁ is Y or G, X₂ is P or S, X₃ is A or F, X₄ is N or D, and

(iii) the CDR-3H sequence is GNYFDY (SEQ ID NO:3) or GLAAPRS (SEQ ID NO:11).

[0042] In one embodiment, the invention provides an isolated light chain variable region comprising a CDR-L1, CDR-L2, and CDR-L3, wherein

(i) the CDR-L1 sequence is X₁GX₂X₃LX₄X₅X₆X₇X₈S (SEQ ID NO:187), wherein X₁ is S, Q, or T, X₂ is D, E, or Q, X₃ is K, S, N, I, or A, X₄ is G or R, X₅ is D, S, H, E, or N, X₆ is E, Y, Q, R, or N, X₇ is Y, F, or S, and X₈ is A or S, or SGSX₁SNX₂X₃X₄X₅X₆X₇X₈ (SEQ ID NO:188), wherein X₁ is S, or T, X₂ is I or L, X₃ is E or G, X₄ is T, S, or N, X₅ is N or Y, X₆ is T, P, A, or Y, X₇ is V or L, and X₈ is N, I, or Y, or X₁GX₂SX₃DX₄GX₅YDYVS (SEQ ID NO:189), wherein X₁ is A or T, X₂ is S or T, X₃ is H, S, or N, X₄ is I or V, and X₅ is S or A,

(ii) the CDR-L2 sequence is X₁X₂X₃X₄X₅PS (SEQ ID NO:190), wherein wherein X₁ is Q, D, T, Y, S, or A, X₂ is D, N, S, T, or V, X₃ is D, N, S, T, or Y, X₄ is Q, K, N, or L, and X₅ is R or L, and

(iii) wherein the CDR-L3 sequence is QX₁WX₂X₃X₄X₅X₆X₇X₈ (SEQ ID NO:191), wherein X₁ is A or T, X₂ is D or G, X₃ is R or no amino acid, X₄ is S, F, or N, X₅ is S, T, or N, X₆ is S, T, or P, X₇ is A, V, L, I, or Y, and X₈ is V or L, or AX₁WDDX₂LX₃X₄X₅X₆ (SEQ ID NO:192, wherein X₁ is A, S, or T, X₂ is N or S, X₃ is N, I, or G, X₄ is G or S, X₅ is P, W, or V, and X₆ is V or L, or MYSTITX₁LL (SEQ ID NO:193), wherein X₁ is A or T.

[0043] In one embodiment, the invention provides an isolated light chain variable region comprising a CDR-L1, CDR-L2, and CDR-L3, wherein

(i) the CDR-L1 sequence is RASX₁X₂X₃X₄X₅X₆X₇YX₈X₉ (SEQ ID NO:194), wherein X₁ is Q, E, or H, X₂ is S, R, or N, X₃ is V, I, or L, X₄ is S, R, G or N, X₅ is S or N, X₆ is S, N, W, or D, X₇ is G or no amino acid, X₈ is L or F, and X₉ is A, G, M, or S,

(ii) the CDR-L2 sequence is GASX₁RAT (SEQ ID NO:195), wherein X₁ is S, T, I, or N, and

(iii) the CDR-L3 sequence is QQX₁X₂X₃X₄X₅X₆X₇X₈ (SEQ ID NO:196), wherein X₁ is F or Y, X₂ is D, G, or Y, X₃ is S, T, or N, X₄ is S, L, or W, X₅ is P or no amino acid, X₆ is P or T, X₇ is L, I, V, P, W, or Y, and X₈ is T or S.

[0044] In an embodiment of the invention, an antibody is provided which comprises a heavy chain variable domain comprising one, two, three, four, five, or six of the light chain variable domain and heavy chain variable domain CDR sequences set forth above.

[0045] Non-limiting examples of VEGFR2-binding antibody sequences are provided. As described herein, from human Fab phage display libraries, two neutralizing antibodies were identified that bind to human VEGFR2, block binding of the ligand VEGFA to hVEGFR2, and inhibit the VEGFR2 phosphorylation and downstream signal transduction stimulated by VEGFA. Table 1 indicates amino acid sequences of the CDRs and variable domains of antibodies of the antibodies. The K_ds of Mab 101 and Mab 102 are about 6.6 mM and 1.7 nM, respectively.

Table 1 - Antibody Amino Acid Sequences by SEQ ID NO								
Mab	CDR-H1	CDR-H2	CDR-H3	V _H domain	CDR-L1	CDR-L2	CDR-L3	V _L domain
101	1	2	3	4	5	6	7	8
102	9	10	11	12	13	14	15	16

[0046] The heavy chain of Mab 101 was reshuffled with κ light chain genes (κ -library) and λ light chain genes (λ -library). 20 unique λ light chain variants were found by panning the λ -library against both human VEGFR2 and mouse VEGFR2. 22 unique κ light chain variants were found by panning the κ -library against both human VEGFR2 and mouse VEGFR2. Table 2 indicates amino acid sequences of the CDRs and variable domains of the light chains. The K_ds of Mabs 105, 106, and 107 were increased about 10 fold (0.24 nM, 0.22 nM, and 0.12 nM, respectively). Like the parent antibody, these antibodies bind to VEGFR2 and block binding of VEGFA to VEGFR2, and inhibit VEGFA-stimulated phosphorylation of VEGFR2, AKT, and MAPK. (Fig. 4).

[0047] Several of the antibodies, including Mabs 138, 139, 140, and 146, also cross react with mouse VEGFR2. These antibodies also inhibited VEGFA-stimulated phosphorylation of VEGFR2 and downstream signal transduction molecules, including MAPK.

Table 2 - κ and λ light chains by SEQ ID NO											
Mab	light chain	SEQ ID NO				Mab	light chain	SEQ ID NO			
		CDR -L1	CDR -L2	CDR -L3	V _L			CDR -L1	CDR -L2	CDR -L3	V _L
103	λ	17	18	19	20	124	κ	101	102	103	104
104	λ	21	22	23	24	125	κ	105	106	107	108
105	λ	25	26	27	28	126	κ	109	110	111	112
106	λ	29	30	31	32	127	κ	113	114	115	116
107	λ	33	34	35	36	128	κ	117	118	119	120
108	λ	37	38	39	40	129	κ	121	122	123	124
109	λ	41	42	43	44	130	κ	125	126	127	128
110	λ	45	46	47	48	131	κ	129	130	131	132
111	λ	49	50	51	52	132	κ	133	134	135	136
112	λ	53	54	55	56	133	κ	137	138	139	140
113	λ	57	58	59	60	134	κ	141	142	143	144
114	λ	61	62	63	64	135	κ	145	146	147	148
115	λ	65	66	67	68	136	κ	149	150	151	152
116	λ	69	70	71	72	137	κ	153	154	155	156
117	λ	73	74	75	76	138	κ	157	158	159	160
118	λ	77	78	79	80	139	κ	161	162	163	164
119	λ	81	82	83	84	140	κ	165	166	167	168
120	λ	85	86	87	88	141	κ	169	170	171	172
121	λ	89	90	91	92	142	κ	173	174	175	176
122	λ	93	94	95	96	143	κ	177	178	179	180
123	κ	97	98	99	100	144	κ	181	182	183	184

[0048] The invention provides an isolated VEGFR2 antibody, and VEGFR2 binding fragments thereof, which comprises one, two, or three heavy chain CDRs and one, two, or three light chain CDRs, selected from the sequences set forth in Table 1 and Table 2. In an antibody of the invention, when more than one CDR is selected from the sequences presented in Table 1 and Table 2, the different CDRs need not be selected from the same monoclonal antibody presented in those tables, but can be selected from two or more antibody variable domains presented in the tables. Specific embodiments include, but are not limited to, the following. In an embodiment of the invention, the isolated VEGFR2 antibody comprises one, two, or three heavy chain CDRs having SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. In

an embodiment, of the invention, the antibody comprises one, two, or three light chain CDRs having SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. In another embodiment, the antibody comprises one, two, or three light chain CDRs having sequences as set forth in Table 1 or 2. Non-limiting examples include a light chain variable region comprising one or more of SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, one or more of SEQ ID NO:29, SEQ ID NO:30, and SEQ ID NO:31, or one or more of SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35. In certain embodiments, the VEGFR2 antibody comprises a heavy chain variable domain comprising SEQ ID NO:4 or SEQ ID NO:12. In certain embodiments, the VEGFR2 antibody comprises a light chain variable domain comprising SEQ ID NO:8, SEQ ID NO:16, SEQ ID NO:27, SEQ ID NO:31, or SEQ ID NO:35. In certain embodiments, the antibodies comprise one of the above-mentioned heavy chain variable domains and one of the above-mentioned light chain variable domains. In certain embodiments, the VEGFR2 antibodies or binding fragments thereof comprise one or more CDRs or one or more variable domains with an amino acid sequence at least 85% at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, identical to the CDR and variable domain sequences set forth in Table 1 or 2. In certain embodiments, antibodies of the invention have CDR amino acids identical to those disclosed herein and frameworks that are at least 85%, at least 90%, or at least 95% identical.

[0049] “Identity” refers to the number or percentage of identical positions shared by two amino acid or nucleic acid sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. “Substantially identical” means an amino acid sequence that which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein. Preferably, the amino acid sequence is at least 80%, more preferably at least 85%, and most preferably at least 90% similar to another amino acid sequence. Methods and computer programs for determining sequence similarity are publically available, including, but not limited to, the GCG program package (Devereux et al., Nucleic Acids Research 12: 387, 1984), BLASTP, BLASTN, FASTA (Altschul et al., J. Mol. Biol. 215:403 (1990), and the ALIGN program (version 2.0). The well-known Smith Waterman algorithm may also be used to determine similarity. The BLAST program is publicly available from NCBI and other sources (BLAST Manual,

Altschul, et al., NCBI NLM NIH, Bethesda, Md. 20894; BLAST 2.0 at <http://www.ncbi.nlm.nih.gov/blast/>). In comparing sequences, these methods account for various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0050] Antibodies of the invention also include those for which binding characteristics have been improved by direct mutation, methods of affinity maturation, phage display, or chain shuffling. Affinity and specificity may be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics. CDRs are mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that in a population of otherwise identical antigen binding sites, all twenty amino acids are found at particular positions. Alternatively, mutations are induced over a range of CDR residues by error prone PCR methods (see, e.g., Hawkins et al., *J. Mol. Biol.*, 226: 889-896 (1992)). For example, phage display vectors containing heavy and light chain variable region genes may be propagated in mutator strains of *E. coli* (see, e.g., Low et al., *J. Mol. Biol.*, 250: 359-368 (1996)). These methods of mutagenesis are illustrative of the many methods known to one of skill in the art.

[0051] To minimize the immunogenicity of antibodies that bind to VEGF receptors, the present invention provides antibodies which comprise human variable and constant domain sequences. The antibodies may be or may combine members of any immunoglobulin class, such as IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof. The antibody class may be selected to optimize effector functions (e.g., complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC)) of natural antibodies.

[0052] Certain embodiments of the invention involve the use of VEGFR2-binding antibody fragments. An Fv is the smallest fragment that contains a complete heavy and light chain variable domain, including all six hypervariable loops (CDRs). Lacking constant domains, the variable domains are noncovalently associated. The heavy and light chains may be connected into a single polypeptide chain (a “single-chain Fv” or “scFv”) using a linker that allows the V_H and V_L domains to associate to form an antigen binding site. In an embodiment of the invention, the linker is (Gly-Gly-Gly-Gly-Ser)₃. Since scFv fragments lack the constant domains of whole antibodies, they are considerably smaller than whole

antibodies. scFv fragments are also free of normal heavy-chain constant domain interactions with other biological molecules which may be undesired in certain embodiments.

[0053] Fragments of an antibody containing V_H , V_L , and optionally C_L , C_{H1} , or other constant domains can also be used. Monovalent fragments of antibodies generated by papain digestion are referred to as Fab and lack the heavy chain hinge region. Fragments generated by pepsin digestion, referred to as $F(ab')_2$, retain the heavy chain hinge and are divalent. Such fragments may also be recombinantly produced. Many other useful antigen-binding antibody fragments are known in the art, and include, without limitation, diabodies, triabodies, single domain antibodies, and other monovalent and multivalent forms.

[0054] The invention further provides multivalent antigen-binding proteins, which can be in the form, without limitation, of antibodies, antigen-binding fragments thereof, and proteins comprising all or part of antigen-binding portions of antibodies. Multivalent antigen-binding proteins may be monospecific, bispecific, or multispecific. The term specificity refers to the number of different types of antigenic determinants to which a particular molecule can bind. If an immunoglobulin molecule binds to only one type of antigenic determinant, the immunoglobulin molecule is monospecific. If the immunoglobulin molecule binds to different types of antigenic determinants then the immunoglobulin molecule is multispecific.

[0055] For example, a bispecific multivalent single chain antibody allows for the recognition of two different types of epitopes. Both epitopes may be on the same antigen (e.g., VEGFR2). Alternatively, one epitope may be on one antigen (e.g., VEGFR2), and the second epitope on a different antigen.

[0056] In one embodiment, a multivalent single chain antibody includes a variable light-chain fragment linked to a variable heavy-chain fragment (similar to an scFv), which is further linked by another peptide linker to at least one other antigen binding domain. Typically, the peptide linker is composed of about fifteen amino acid residues. In a preferred embodiment, the number of V_L and V_H domains is equivalent. For example, a bivalent single chain antibody can be represented as follows: $V_L-L_1-V_H-L_2-V_L-L_3-V_H$ or $V_L-L_1-V_H-L_2-V_H-L_3-V_L$ or $V_H-L_1-V_L-L_2-V_H-L_3-V_L$ or $V_H-L_1-V_L-L_2-V_L-L_3-V_H$. Multivalent single chain antibodies which are trivalent or greater have one or more antibody fragments joined to a bivalent single chain antibody by additional peptide linkers. One example of a trivalent single chain antibody is: $V_L-L_1-V_H-L_2-V_L-L_1-V_H-L_2-V_L-L_1-V_H$.

[0057] Two single chain antibodies can be combined to form a diabody, also known as bivalent dimer. Diabodies have two chains. Each chain of the diabody includes a V_H domain connected to a V_L domain by a short linker of about 5-10 amino acid residues, e.g. (Gly-Gly-Gly-Gly-Ser), (Gly-Gly-Gly-Gly-Ser)₂. Such linkers are short enough to prevent intrachain pairing between domains on the same chain, thus driving interchain pairing between complementary domains on different chains and recreate two antigen-binding sites. The diabody structure is rigid and compact, with antigen-binding sites are at opposite ends of the molecule. Diabodies may be monospecific or bispecific.

[0058] Three single chain antibodies can be combined to form a triabody, also known as a trivalent trimers. In some embodiments, triabodies are constructed with the carboxy terminus of a V_L or V_H domain directly fused to the amino terminus of a V_H or V_L domain, i.e., without any linker sequence. The triabody has three Fv heads with the polypeptides arranged in a cyclic, head-to-tail fashion. A possible conformation of the triabody molecule is planar with the three binding sites located in a plane at an angle of 120 degrees from one another. Triabodies may be monospecific, bispecific or trispecific.

[0059] It is understood that the anti-VEGFR2 antibodies of the invention, where used in a mammal for the purpose of prophylaxis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibodies.

[0060] In the methods of the present invention, a therapeutically effective amount of an antibody of the invention is administered to a mammal in need thereof. The term “administering” as used herein means delivering the antibodies of the present invention to a mammal by any method that may achieve the result sought. They may be administered, for example, intravenously or intramuscularly. Although human antibodies of the invention are particularly useful for administration to humans, they may be administered to other mammals as well. The term “mammal” as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals. “Therapeutically effective amount” means an amount of antibody of the present invention that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase

activity. For example, depending on the disease, for an antibody, this may require 0.1, 1.0, 3.0, 6.0, or 10.0 mg/Kg. For an IgG having a molecular mass of 150,000 g/mole (two binding sites), these doses correspond to approximately 18 nM, 180 nM, 540 nM, 1.08 μ M, and 1.8 μ M of binding sites for a 5 L blood volume.

[0061] Antibodies of the invention are useful for inhibiting tumor growth, angiogenesis associated with tumor growth, or other pathologic condition associated with angiogenesis. Tumors that can be treated include primary tumors, metastatic tumors, and refractory tumors. Refractory tumors include tumors that fail to respond or are resistant to treatment with chemotherapeutic agents alone, antibodies alone, radiation alone or combinations thereof. Refractory tumors also encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued. The antibodies are effective for treating vascularized tumors and tumor that are not vascularized, or not yet substantially vascularized.

[0062] Examples of solid tumors which may be accordingly treated include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma. Some examples of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. Other examples include Kaposi's sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma. Examples of vascularized skin cancers for which the antagonists of this invention are effective include squamous cell carcinoma, basal cell carcinoma and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes.

[0063] Examples of non-solid tumors include leukemia, multiple myeloma and lymphoma. Some examples of leukemias include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), erythrocytic leukemia or monocytic leukemia. Some examples of lymphomas include Hodgkin's and non-Hodgkin's lymphoma.

[0064] Antibodies of the invention can also be used to treat or preventing pathologic conditions characterized by excessive angiogenesis, involving, for example, vascularization and/or inflammation, such as atherosclerosis, rheumatoid arthritis (RA), hemangiomas, angiofibromas, and psoriasis. Other non-limiting examples of non-neoplastic angiogenic disease are retinopathy of prematurity (retrolental fibroplastic), corneal graft rejection, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary cirrhosis, acute pancreatitis, allograft rejection, allergic inflammation, contact dermatitis and delayed hypersensitivity reactions, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, cognition defects induced by neuronal inflammation, Osler-Weber syndrome, restinosis, and fungal, parasitic and viral infections, including cytomegaloviral infections.

[0065] Ocular diseases characterized by excessive angiogenesis include neovascular glaucoma, proliferative retinopathy including proliferative diabetic retinopathy, and macular degeneration. The invention provides methods and compounds for treating ocular diseases and disorders. In one embodiment, the invention provides for treating age related macular degeneration (AMD), which occurs in “dry” and “wet” forms. The “wet” form of AMD causes vision loss due to abnormal blood vessel growth (neovascularization). Bleeding, leaking, and scarring from these retinal blood vessels eventually causes irreversible damage to the photoreceptors. The dry form results from atrophy of the retinal pigment epithelial layer, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye. In another embodiment, the invention provides a method of treating choroidal neovascularization (CNV). Choroidal neovascularization is a process in which new blood vessels grow in the choroid, through the Bruch membrane and invade the subretinal space, and is a symptom of, among other causes, age-related macular degeneration, myopia and ocular trauma. In another embodiment, the invention provides a method of treating diabetic macular edema (DME). In another embodiment, the invention provides a method of treating macular edema that is secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Other diseases treatable according to the invention include, without limitation, iris neovascularization, uveitis, neovascular glaucoma, and retinitis of prematurity (ROP). The method of treatment can be prophylactic, such as to stave off corneal neovascularization after corneal transplant, or to modulate the wound healing process in trabeculectomy surgery.

[0066] Antibodies and antigen binding fragments of the invention can be advantageously administered with second agents to patients in need thereof. For example, in some embodiments, a VEGFR-2 antibody of the invention is administered to a subject with an anti-neoplastic agent. In some embodiments, a VEGFR-2 antibody is administered to a subject with a second angiogenesis inhibitor. In some embodiments, a VEGFR-2 antibody of the invention is administered with an anti-inflammatory agent or an immunosuppressant.

[0067] Antineoplastic agents include cytotoxic chemotherapeutic agents, targeted small molecules and biological molecules, and radiation. Non-limiting examples of chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, irinotecan, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, plicamycin, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, taxol and combinations thereof.

[0068] Targeted small molecules and biological molecules include, without limitation, inhibitors of components of signal transduction pathways, such as modulators of tyrosine kinases and inhibitors of receptor tyrosine kinases, and agents that bind to tumor-specific antigens. Non-limiting examples of growth factor receptors involved in tumorigenesis are the receptors for platelet-derived growth factor (PDGFR), insulin-like growth factor (IGFR), nerve growth factor (NGFR), and fibroblast growth factor (FGFR), and receptors of the epidermal growth factor receptor family, including EGFR (erbB1), HER2 (erbB2), erbB3, and erbB4.

[0069] EGFR antagonists include antibodies that bind to EGFR or to an EGFR ligand, and inhibits ligand binding and/or receptor activation. For example, the agent can block formation of receptor dimers or heterodimer with other EGFR family members. Ligands for EGFR include, for example, EGF, TGF- α amphiregulin, heparin-binding EGF (HB-EGF) and betarecullulin. An EGFR antagonist can bind externally to the extracellular portion of EGFR, which may or may not inhibit binding of the ligand, or internally to the tyrosine kinase domain. EGFR antagonists further include agents that inhibit EGFR-dependent signal

transduction, for example, by inhibiting the function of a component of the EGFR signal transduction pathway. Examples of EGFR antagonists that bind EGFR include, without limitation, biological molecules, such as antibodies (and functional equivalents thereof) specific for EGFR, and small molecules, such as synthetic kinase inhibitors that act directly on the cytoplasmic domain of EGFR.

[0070] Small molecule and biological inhibitors include inhibitors of epidermal growth factor receptor (EGFR), including gefitinib, erlotinib, and cetuximab, inhibitors of HER2 (e.g., trastuzumab, trastuzumab emtansine (trastuzumab-DM1; T-DM1) and pertuzumab), anti-VEGF antibodies and fragments (e.g., bevacizumab), antibodies that inhibit CD20 (e.g., rituximab, ibritumomab), anti-VEGFR antibodies (e.g., ramucirumab (IMC-1121B), IMC-1C11, and CDP791), anti-PDGFR antibodies, and imatinib. Small molecule kinase inhibitors can be specific for a particular tyrosine kinase or be inhibitors of two or more kinases. For example, the compound N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c] pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine (also known as XL647, EXEL-7647 and KD-019) is an *in vitro* inhibitor of several receptor tyrosine kinases (RTKs), including EGFR, EphB4, KDR (VEGFR), Flt4 (VEGFR3) and ErbB2, and is also an inhibitor of the SRC kinase, which is involved in pathways that result in nonresponsiveness of tumors to certain TKIs. In an embodiment of the invention, treatment of a subject in need comprises administration of a rho-kinase inhibitor of Formula I and administration of KD-019.

[0071] Dasatinib (BMS-354825; Bristol-Myers Squibb, New York) is another orally bioavailable, ATP-site competitive Src inhibitor. Dasatinib also targets Bcr-Abl (FDA-approved for use in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome positive (Ph⁺) acute lymphoblastic leukemia (ALL)) as well as c-Kit, PDGFR, c-FMS, EphA2, and SFKs. Two other oral tyrosine kinase inhibitor of Src and Bcr-Abl are bosutinib (SKI-606) and saracatinib (AZD0530).

[0072] While VEGFR2 mediates the majority of the downstream effects of VEGF in angiogenesis, it can be advantageous to administer a second angiogenesis inhibitor. Anti-VEGFR-2 antibodies of the invention may be administered with antibodies that neutralize other receptors involved in tumor growth or angiogenesis.

[0073] Non-limiting examples of VEGF-binding agents include VEGF antibodies and VEGF traps (i.e., ligand binding domains of VEGF receptors). Two examples of antibodies

(including VEGF-binding antibody fragments) are bevacizumab (Avastin), an antibody which binds to VEGF-A, and ranibizumab (Lucentis), an Fab derived from bevacizumab. In general, a VEGF trap is a protein that comprises VEGF binding domains of one or more VEGF receptor protein. VEGF-traps include, without limitation, soluble VEGFR-1, soluble neuropilin 1 (NRP1), soluble VEGFR-3 (which binds VEGF-C and VEGF-D), and aflibercept (Zaltrap; Eylea; VEGF Trap R1R2), comprised of segments of the extracellular domains of human vascular endothelial growth factor receptors VEGFR1 and VEGFR2 fused to the constant region (Fc) of human IgG1. Conbercept (KH902) is a fusion protein which contains the extracellular domain 2 of VEGFR-1 (Flt-1) and extracellular domain 3, 4 of VEGFR-2 (KDR) fused to the Fc portion of human IgG1. Several VEGF traps containing KDR and FLT-1 Ig-like domains in various combinations are disclosed in U.S. Patent 8,216,575. DARPins (an acronym for designed ankyrin repeat proteins) are genetically engineered antibody mimetic proteins typically exhibiting highly specific and high-affinity target protein binding. DARPIn® MP0112 is a vascular endothelial growth factor (VEGF) inhibitor and has entered clinical trials for the treatment of wet macular degeneration and diabetic macular edema.

[0074] According to the invention, VEGF expression can be targeted. For example, VEGF inhibitor PTC299 targets VEGF post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. Pegaptanib (Macugen) is an RNA aptamer directed against VEGF-165.

[0075] Placental growth factor (PlGF) has been implicated in pathological angiogenesis. PlGF is structurally related to VEGF and is also a ligand for VEGFR-1. Consequently, VEGF traps comprising the extracellular domain of VEGFR1 (see above) are useful for targeting PlGF. Anti-angiogenic agents further include those that bind to the VEGFR-1/Flt-1 receptor. In certain embodiments, the antigen-binding proteins that bind to the extracellular domain of VEGFR-1 block binding by one or both of its ligands, VEGF and PlGF, and/or neutralize VEGF-induced or PlGF-induced activation of VEGFR-1.

[0076] PDGF is composed of four polypeptide chains that form homodimers PDGF-AA, BB, CC, and DD as well as the heterodimer PDGF-AB. The PDGF receptors (PDGFR) α and β mediate PDGF functions. Specifically, PDGFR α binds to PDGF-AA, -BB, -AB, and -CC, whereas PDGFR β interacts with -BB and -DD. Non-limiting examples of PDGF-binding agents include anti-PDGF antibodies and PDGF traps. Agents that target PDGF include Fovista™ (E10030, Ophthotech), a pegylated aptamer targeting PDGF-B, and AX102

(Sennino et al., 2007, Cancer Res. 75(15):7359-67), a DNA oligonucleotide aptamer that binds PDGF-B.

[0077] In certain embodiments of the present invention, an antibody or an antigen binding fragment thereof is administered to a subject together with an effective amount of a PDGFR β antibody

[0078] Agents that target PDGF receptors include ramucirumab (IMC-3G3, human IgG₁) an anti-PDGFR α antibody, crenolanib (CP-868596), a selective inhibitor of PDGFR α (IC₅₀ = 0.9 nM) and PDGFR β (IC₅₀ = 1.8 nM), and nilotinib (Tasigna®), an inhibitor of PDGFR α and PDGFR β and other tyrosine kinases.

[0079] Angiogenesis inhibitors include intracellular agents that block signal transduction mediated by, for example, VEGF, PDGF, ligands of VEGF or PDGF receptors, or complement. Intracellular agents that inhibit angiogenesis inhibitors include the following, without limitation. Sunitinib (Sutent; SU11248) is a panspecific small-molecule inhibitor of VEGFR1–VEGFR3, PDGFR α and PDGFR β , stem cell factor receptor (cKIT), Flt-3, and colony-stimulating factor-1 receptor (CSF-1R). Axitinib (AG013736; Inlyta) is another small molecule tyrosine kinase inhibitor that inhibits VEGFR-1-VEGFR-3, PDGFR, and cKIT. Cediranib (AZD2171) is an inhibitor of VEGFR-1-VEGFR-3, PDGFR β , and cKIT. Sorafenib (Nexavar) is another small molecular inhibitor of several tyrosine protein kinases, including VEGFR, PDGFR, and Raf kinases. Pazopanib (Votrient; GW786034) inhibits VEGFR-1, -2 and -3, cKIT and PDGFR. Foretinib (GSK1363089; XL880) inhibits VEGFR2 and MET, as does cabozantinib (Cometriq; XL184). Ponatinib (Iclusig; AP24534) inhibits VEGFR, PDGFR and c kit. Tivozanib (AV-951) inhibits VEGFR-1, VEGFR-2 and VEGFR-3 at picomolar concentrations. CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases. E-3810 ((6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide) inhibits VEGFR-1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range. Brivanib (BMS-582664) is a VEGFR-2 inhibitor that also inhibits FGF receptor signaling. CT-322 (Adnectin) is a small protein based on a human fibronectin domain and binds to and inhibits activation of VEGFR2. Vandetanib (Caprelas; Zactima; ZD6474) is an inhibitor of VEGFR2, EGFR, and RET tyrosine kinases. X-82 (Xcovery) is a small molecule indolinone inhibitor of signaling through the growth factor receptors VEGFR and PDGFR.

[0080] In certain embodiments, anti-VEGFR antibodies of the invention are coadministered with matrix metalloproteinase inhibitors. Matrix metalloproteases (MMPs), such as MMP-14, MMP-16, and MMP-24, cleave components of the extracellular matrix (ECM) and basement membranes, thereby allowing cancer cells to penetrate and infiltrate the subjacent stromal matrix. Additionally, a number of growth-factor receptors, cell adhesion molecules, chemokines, cytokines, apoptotic ligands, and angiogenic factors are substrates of MMPs. Hence, MMP activity may cause activation of growth factors, suppression of tumor cell apoptosis, destruction of chemokine gradients developed by host immune response, or release of angiogenic factors. MMPs may facilitate tumor growth by promoting the release of cell proliferation factors such as insulin-like growth factors which are bound to specific binding proteins (IGFBPs) (Manes et al., 1997 J. Biol. Chem. 272: 25706-25712).

[0081] Collagenases, including MMP-2, have been found at elevated levels in melanoma and in cancers of the colon, breast, lung, prostate, and bladder. Usually, these elevated levels correlate with higher tumor grade and invasiveness. MMP-2 levels are significantly elevated in the serum of patients with metastatic lung cancer, and in those patients with high levels, response to chemotherapy is diminished. MMP-14, which cleaves proMMP-2 to release active MMP-2, is elevated in numerous cancers and can contribute to the growth of tumors, tumor embolism, and the mobility, invasiveness and metastasis of cancer (e.g., CNS tumors (e.g., gliomas), head and neck cancer, oral cavity cancer, laryngeal cancer, chondrosarcoma, breast cancer). MMP-16 and MMP-24 are also elevated in numerous cancers and can contribute to both the growth of tumors and the invasiveness and metastasis of cancer (e.g., breast cancer, laryngeal cancer, ovarian cancer, testicular carcinoma, melanoma, brain tumors (e.g., astrocytomas, glioblastomas, gliomas)).

[0082] In certain embodiments, anti-VEGFR antibodies of the invention are coadministered with MMP-14 antagonists, including but not limited to anti-MMP-14 antibodies disclosed in U.S. Patents 7,745,587 and 8,106,168. In one embodiment, the antibody is human monoclonal antibody DX-2400 (Dyax Corp). Coadministration with such an antibody is suitable for treatment of human carcinomas, including but not limited to, uterine cervix, stomach, lung, breast, colon, head and neck, malignant brain tumors, and melanoma.

[0083] In another embodiment, a VEGFR2 antibody of the invention can be administered in combination with one or more suitable adjuvants, such as, for example, cytokines (IL-10 and IL-13, for example) or other immune stimulators. It should be

appreciated, however, that administration of only an anti-KDR antibody is sufficient to prevent, inhibit, or reduce the progression of the tumor in a therapeutically effective manner.

[0084] Anti-inflammatories and immunosuppressants include steroid drugs such as glucocorticoids (e.g., dexamethasone), FK506 (tacrolimus), ciclosporin, fingolimod, interferon, such as IFN β or IFN γ , a tumor necrosis factor-alpha (TNF- α) binding protein such as infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira), and mycophenolic acid.

[0085] Certain embodiments comprise administering an antibody of the invention and a second agent as follows: docetaxel for solid tumors, including breast cancer and urinary tract and renal cancers, paclitaxel (solid tumors, gastric adenocarcinoma), FOLFRI (i.e., irinotecan, folinic acid, 5-Fluorouracil) for colorectal cancer, capecitabine (breast cancer), FOLFOX (i.e., oxaliplatin, leucovorin, 5-Fluorouracil) (gastric, esophageal, gastroesophageal cancers), eribulin (breast cancer), FOLFIRI (i.e., irinotecan, levofolinate, 5-Fluorouracil) (colorectal carcinoma), carboplatin (NSCLC), mitoxantrone and prednisone (prostate cancer), OFF (oxaliplatin folinic acid, 5-Fluorouracil) (colorectal cancer), irinotecan and cetuximab (colorectal cancer), and dacarbazine (malignant melanoma).

[0086] The antibodies and antigen binding fragments of the invention can be conjugated to an agent, e.g., a cytotoxic drug, cytotoxin enzyme, or radioisotope. This method includes administering the binding protein alone or attached to an agent (e.g., a cytotoxic drug), to a subject requiring such treatment. For example, VEGFR2 antibodies or fragments thereof may be used to deliver nanoparticles containing agents, such as toxins, to VEGFR2 associated cells or tissues, e.g., tumors.

[0087] The VEGFR2 binding proteins can be used directly in vivo to eliminate antigen-expressing cells via natural complement-dependent cytotoxicity (CDC) or antibody dependent cellular cytotoxicity (ADCC). The binding proteins described herein can include complement binding effector domain, such as the Fc portions from IgG1, -2, or -3 or corresponding portions of IgM which bind complement.

[0088] When a VEGFR-2 antibody of the invention is administered with a second agent, the first and second agents can be administered sequentially or simultaneously. Each agent can be administered in single or multiple doses, and the doses can be administered on any schedule, including, without limitation, twice daily, daily, weekly, every two weeks, and monthly.

[0089] The invention also includes adjunctive administration. Adjunctive administration means that a second agent is administered to a patient in addition to a first agent that is already being administered to treat a disease or disease symptom. In some embodiments, adjunctive administration includes administering a second agent to a patient in which administration of the first agent did not treat, or did not sufficiently treat, the disease or disease symptom. In other embodiments, adjunctive administration includes administration of the second agent to a patient whose disease has been effectively treated by administration of the first agent.

[0090] In one embodiment of the invention, an antibody or an antigen binding fragment thereof is administered by injection, a small molecule administered orally. In one such embodiment, the antibody is administered weekly or once or twice per month and the small molecule is administered daily.

[0091] In an embodiment of the invention, an antibody or an antigen binding fragment thereof is administered by injection, and a ROCK2 inhibitor is administered orally. In a preferred embodiment, the agents are administered once daily. According to the invention, when a ROCK inhibitor, or a VEGFR2 antibody are administered to a subject to treat an ocular disease, a TGF- β antagonist can be administered to the subject to reduce or prevent scarring. For example, in an embodiment of the invention, when a ROCK inhibitor is administered to treat an ocular disorder, a TGF- β antagonist is also administered. In another embodiment, when a VEGF antagonist is administered to a subject to treat an ocular disorder, a TGF- β antagonist is also administered. In another embodiment of the invention, when a ROCK inhibitor and a VEGF antagonist are administered to a subject to treat an ocular disorder, a TGF- β antagonist is also administered. In ocular diseases involving neovascularization, leakage of new blood vessels is followed by scar formation (e.g., disciform scar). The invention includes administration of a TGF- β antagonist as well as a VEGF antagonist and a ROCK2 inhibitor to a subject to treat neovascularization in ocular disease.

[0092] Useful TGF- β antagonists include, without limitation, the following: (i) anti-TGF- β antibodies and antigen binding fragments thereof, such as pan-TGF- β antibody GC-1008 (Genzyme), anti-TGF- β_1 antibody metelimumab (CAT-192) (Cambridge Antibody Technology), and antigen binding fragments of those antibodies, (ii) soluble TGF- β receptors or ligand binding fragments thereof, such as P144, a synthetic peptide encompassing amino acids 730–743 from the membraneproximal ligand-binding domain of TGF- β type III

receptor (Esparza-López et al., 2001, J. Biol. Chem. 276(18):14588-96), and a type II TGF- β receptor – Fc (IgG₁) fusion (Smith, J. et al., 1999, Circulation Res. 84:1212-22), (iii) peptides that bind to TGF- β receptors that block one or more isoforms of TGF- β , such as the 25 amino acid peptides from TGF- β ₁, TGF- β ₂, and TGF- β ₃ disclosed by Huang et al., 1997, J. Biol. Chem. 272:27155-59, that bind to TGF- β receptors, and (iv) antisense agents that inhibit TGF- β synthesis, such as trabedersen (Antisense Pharma GmbH), an oligonucleotide that inhibits the synthesis of TGF- β ₂. Additional antagonists are disclosed in WO2006/052568, WO 02/094833, WO 04/048382, WO 04/048381, WO 04/050659, WO 04/021989, WO 04/026871, and WO 04/026307.

[0093] In certain embodiments of the present invention, an antibody or an antigen binding fragment thereof is administered to a subject together with an effective amount of a PD-L1 antibody (see US 61/927,907 and PCT/US15/11657, which are incorporated herein by reference in their entirety).

[0094] In certain embodiments, a dose of a compound or a composition is administered to a subject every day, every other day, every couple of days, every third day, once a week, twice a week, three times a week, or once every two weeks. In other embodiments, two, three or four doses of a compound or a composition is administered to a subject every day, every couple of days, every third day, once a week or once every two weeks. In some embodiments, a dose(s) of a compound or a composition is administered for 2 days, 3 days, 5 days, 7 days, 14 days, or 21 days. In certain embodiments, a dose of a compound or a composition is administered for 1 month, 1.5 months, 2 months, 2.5 months, 3 months, 4 months, 5 months, 6 months or more.

[0095] Methods of administration include but are not limited to parenteral, intradermal, intravitreal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, transmucosal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of a compound into the bloodstream. For treatment of ocular disease, intravitreal administration of biological agents is preferred.

[0096] In specific embodiments, it may be desirable to administer a compound locally. This may be achieved, for example, and not by way of limitation, by local infusion, topical application, by injection, by means of a catheter, or by means of an implant, said

implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In such instances, administration may selectively target a local tissue without substantial release of a compound into the bloodstream.

[0097] Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, a compound is formulated as a suppository, with traditional binders and vehicles such as triglycerides.

[0098] In another embodiment, a compound is delivered in a vesicle, in particular a liposome (See Langer, 1990, Science 249:1527 - 1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Bacterial infection, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353 - 365 (1989); Lopez Berestein, *ibid.*, pp. 317 - 327; see generally *ibid.*).

[0099] In another embodiment, a compound is delivered in a controlled release system (See, e.g., Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115 - 138 (1984)). Examples of controlled-release systems are discussed in the review by Langer, 1990, Science 249:1527 - 1533 may be used. In one embodiment, a pump may be used (See Langer, *supra*; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used (See Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; See also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).

[00100] The above-described administration schedules are provided for illustrative purposes only and should not be considered limiting. A person of ordinary skill in the art will readily understand that all doses are within the scope of the invention.

[00101] It is to be understood and expected that variations in the principles of invention herein disclosed may be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention.

[00102] Throughout this application, various publications are referenced. These publications are hereby incorporated into this application by reference in their entireties to

more fully describe the state of the art to which this invention pertains. The following examples further illustrate the invention, but should not be construed to limit the scope of the invention in any way.

EXAMPLES

Example 1

Identification of antibodies that bind to VEGFR domains 2 and 3 and block ligand binding.

[00103] Two antibodies that bind to and neutralize human VEGFR2, identified in Table 1, were isolated from human Fab phage display libraries. The antibodies block binding of the ligand VEGFA to hVEGFR2 (Fig. 2). The antibodies also bind to porcine aortic endothelial (PAE) cells expressing KDR, and inhibit VEGFA-stimulated phosphorylation of VEGFR2, AKT, and MAPK. (Fig. 3). Table 1 indicates amino acid sequences of the CDRs and variable domains of the antibodies. The K_d s of Mab 101 and Mab 102 are about 6.6 mM and 1.7 nM, respectively.

[00104] The heavy chain of Mab 101 was reshuffled with κ light chain genes (κ -library) and λ light chain genes (λ -library). 20 unique λ light chain variants were found by panning the λ -library against both human VEGFR2 and mouse VEGFR2. 22 unique κ light chain variants were found by panning the κ -library against both human VEGFR2 and mouse VEGFR2. Table 2 indicates amino acid sequences of the CDRs and variable domains of the light chains. The K_d s of Mabs 105, 106, and 107 were increased about 10 fold (0.24 nM, 0.22 nM, and 0.12 nM, respectively) (Table 3). These antibodies, and antibody Mab101 from which they are derived, bind to domains 2 and 3 of VEGFR and to constructs containing those domains.

Table 3 – Antibody Binding Data			
Antibody	k_a $10^4 M^{-1} s^{-1}$	k_d $10^{-4} s^{-1}$	KD nM
107	55.8	0.934	0.167
109	30.6	3.80	1.24
104	79.2	1.13	0.165
110	44.9	3.10	0.69
108	71.9	1.75	0.244
105	24.3	0.591	0.243
101	29.8	5.93	1.81

[00105] Like the parent antibody, these antibodies bind to VEGFR2 and block binding of VEGFA to VEGFR2 (Fig. 4), and inhibit VEGFA-stimulated phosphorylation of VEGFR2, AKT, and MAPK (Fig. 5).

[00106] Several of the antibodies, including Mabs 138, 139, 140, and 146, also cross react with mouse VEGFR2.

Table 4 – Cross Reactivity						
	hVEGFR2			mVEGFR2		
Antibody	k_a $10^4\text{M}^{-1}\text{s}^{-1}$	k_d 10^{-4}s^{-1}	KD nM	k_a $10^4\text{M}^{-1}\text{s}^{-1}$	k_d 10^{-4}s^{-1}	KD nM
138	19.7	1.42	0.72	23.4	5.90	2.55
139	14.6	1.75	1.20	13.0	3.17	2.44
106	35.6	0.512	0.144			

Mabs 138, 139, and 140 inhibited VEGFA-stimulated phosphorylation of VEGFR2 and downstream signal transduction molecules, including MAPK.

Example 2

Inhibition of tumor growth *in vivo*

[00107] 6 to 8-week-old sex-matched (female) NOD-SCID mice are irradiated with 3.5 Gy from a ^{137}Cs gamma-ray source at a dose rate of about 0.9 Gy/min and intravenously inoculated with 2×10^7 HL60 cells. Three days after tumor inoculation, groups of mice are treated twice weekly with various doses of Mab 106 and recorded for time of survival.

[00108] All untreated mice died within about two weeks. Even with the high tumor load, the survival time for mice treatment with 10 mg/kg Mab 106 is extended to as much as 28 days.

Example 3

Treatment of Colon Cancer in a Human Patient

[00109] Human subjects diagnosed with colon cancer are divided into treatment groups and given the standard chemotherapeutic regimen. Two patient groups are treated weekly with 5 mg/kg/week or 15 mg/kg/week for 4 months. A control group is given only the standard chemotherapeutic regimen. Tumor burden is assessed periodically by magnetic resonance imaging (MRI). Compared to the control group, it is expected that the patients who have received weekly antibody treatments show significant reductions in tumor growth

or tumor size, increased delay to progression or prolonged survival compared to patients that do not receive the antibody treatment.

[00110] Mab 138 (Table 2), containing the heavy chain of Mab 101 (SEQ ID NO. 4; see Figure 6A), was selected for affinity maturation. Mutations were introduced into CDR3 of the light chain and CDR1, CDR2, and CDR3 of the heavy chain. The resulting library was panned on human and murine VEGFR2. Table 5 indicates amino acid sequences of the heavy and light chain CDRs and variable domains of five of the resulting antibodies. Figure 6 shows a comparison of the sequences to the Mab 138 heavy chain (SEQ ID NO. 4) and kappa light chain (i.e. SEQ ID NO:160).

Table 5 - Antibody Amino Acid Sequences by SEQ ID NO								
Mab #	CDR-H1	CDR-H2	CDR-H3	V _H domain	CDR-L1	CDR-L2	CDR-L3	V _L domain
147 (B1C4_A7)	197	198	199	200	201	202	203	204
148 (B1C4_H9)	205	206	207	208	209	210	211	212
149 (B1C4_E5)	213	214	215	216	217	218	219	220
150 (B1C4_A6)	221	222	223	224	225	226	227	228
151 (B1C4_G3)	229	230	231	232	233	234	235	236

[00111] The binding constants of Mab 147 and Mab 149 as well as the parent Mab 138 for human, murine, and rat VEGFR2 were determined by Biacore analysis (Table 6).

Table 6. Biacore Analysis of Binding to Human, Murine, and Rat VEGFR2				
Mab	antigen	k _a	k _d	K _D
138	rat	4.30E+04	1.34E-03	3.12E-08
	murine	2.86E+04	2.33E-03	8.17E-08
	human	8.98E+04	6.00E-04	6.68E-09
147	rat	6.45E+04	8.99E-04	1.39E-08
	murine	4.38E+04	1.28E-03	2.94E-08
	human	1.13E+05	2.82E-04	2.51E-09
149	rat	3.32E+04	1.43E-03	4.31E-08

	murine	2.29E+04	1.81E-03	7.92E-08
	human	8.62E+04	6.59E-04	7.65E-09

[00112] Mab 147 was examined by ELISA for its receptor binding and ligand blocking properties. Mab 147 binds to both soluble hVEGFR2 and soluble mVEGFR2 with similar affinity (Fig. 7A). Mab 147 blocks ligand binding to hVEGFR2 similar to a hVEGFR specific control antibody and also blocks ligand binding to mVEGFR2 similar to a mVEGFR2-specific control antibody (Fig. 7B).

[00113] Binding of Mab 147 to hVEGFR2 and mVEGFR2 expressed on cell membranes was also confirmed. Fig. 8A shows binding to hVEGFR2 expressed by human umbilical vein endothelial cells (HUVEC) as well as porcine aortic endothelial (PAE) cells overexpressing KDR (i.e., human VEGFR2). Mab 147 also bound to mVEGFR expressed by MS1 murine endothelial cells (Fig. 8B).

[00114] Mab 147 inhibit VEGFR-2 mediated signal transduction, as indicated by reduced phosphorylation of KDR and p42/44 in KDR-PAE cells (Fig. 9A) and in HUVEC cells (Fig. 9B). Mab 106 and Mab 147 inhibit proliferation of KDR-PAE cells (Fig. 10A), as well as inhibit VEGF-induced migration of KDR-PAE cells (Fig 10B). The effect of Mab 147 on inhibition of VEGF-induced migration by KDR-PAE cells is also shown in Fig. 11.

[00115] Mab 147 also inhibits VEGFR-2 mediated signal transduction in murine EOMA cells, as indicated by reduced phosphorylation of mVEGFR2 (Fig. 12A). FACS studies demonstrated that Mab 147 has increased binding to EOMA cells by comparison to control antibodies (Fig. 12B).

CLAIMS

We claim:

1. An isolated antibody or fragment thereof that binds to human VEGFR2, comprising a heavy chain variable domain, which comprises a CDR1, a CDR2, and a CDR3 sequence, wherein:

(i) the CDR1 sequence is GFTFSWYVMG (SEQ ID NO: 237),

(ii) the CDR2 sequence is selected from the group consisting of

SIYPQGGATSYADSVKG (SEQ ID NO: 238),

SIYPQGGATNYADSVKG (SEQ ID NO: 239), and

SIYPSGGATNYADSVKG (SEQ ID NO: 240); and

(ii) the CDR3 sequence selected from the group consisting of

GNYFDY (SEQ ID NO: 241),

GNYLDY (SEQ ID NO: 242),

GPYLDY (SEQ ID NO: 243) and

GSYLDY (SEQ ID NO: 244),

with the proviso that the heavy chain variable domain does not comprise both the CDR2 sequence of SEQ ID NO: 240 and the CDR3 sequence of SEQ ID NO: 241.

2. The antibody or fragment of claim 1, comprising a light chain variable domain, which comprises a CDR1, a CDR2, and a CDR3 sequence, wherein

(i) the CDR1 sequence is RASQSVSSNYFG (SEQ ID NO: 245),

(ii) the CDR2 sequence is GASSRAT (SEQ ID NO: 246), and

(iii) the CDR3 sequence is selected from the group consisting of

QQFDSLPLT (SEQ ID NO: 247),

QQHDSSPLS (SEQ ID NO: 248),

QQFDSSPLS (SEQ ID NO: 249), and

QQFDSSPLT (SEQ ID NO: 250).

3. The antibody or fragment of claim 1, wherein the CDR2 of the heavy chain variable domain has the sequence SIYPQGGATSYADSVKG (SEQ ID NO: 238), and the CDR3 of the heavy chain variable domain has the sequence GNYFDY (SEQ ID NO: 241).
4. The antibody or fragment of claim 2, wherein the CDR3 of the light chain variable domain has the sequence QQFDSLPLT (SEQ ID NO: 247).
5. The antibody or fragment of claim 1, wherein the heavy chain variable domain has a sequence that is selected from the group consisting of SEQ ID NO: 200, SEQ ID NO: 208, SEQ ID NO: 216, SEQ ID NO: 224, and SEQ ID NO: 232.
6. The antibody or fragment of claim 2, wherein the light chain variable domain has a sequence that is selected from the group consisting of SEQ ID NO: 204, SEQ ID NO: 212, SEQ ID NO: 220, SEQ ID NO: 228, and SEQ ID NO: 236.
7. The antibody or fragment of claim 2, wherein the heavy chain variable domain has a sequence that is SEQ ID NO: 200, and wherein the light chain variable domain has a sequence that is SEQ ID NO: 204.
8. The antibody or fragment of any one of claims 1 to 7, which has isotype IgG.
9. The antibody or fragment of any one of claims 1 to 7, which is an scFv, Fv, Fab', Fab, F(ab')₂, or diabody.
10. The antibody or fragment of any one of claims 1-9, wherein the antibody or fragment binds to human VEGFR2 and murine hVEGFR2.
11. An isolated nucleic acid encoding the antibody or fragment of any one of claims 1-10.

12. A nucleic acid vector comprising an isolated nucleic acid according to claim 11.
13. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 11.
14. A composition comprising an antibody or fragment of any one of claims 1-10, and a pharmaceutically acceptable carrier.
15. A method of neutralizing activation of human VEGFR2 or murine VEGFR2 comprising contacting a cell with an effective amount of an antibody or fragment of any one of claims 1-10.
16. A method of inhibiting angiogenesis comprising administering to a subject an effective amount of an antibody or fragment of any one of claims 1-10.
17. A method of reducing tumor growth comprising administering to a subject an effective amount of an antibody or fragment of any one of claims 1-10.
18. A method of treating a neoplastic diseases in a subject, comprising administering to a subject an effective amount of an antibody or fragment of any one of claims 1-10, wherein the neoplastic diseases is selected from the group consisting of lung cancer, colorectal cancer, renal cell carcinoma, glioblastoma, ovarian cancer, bladder cancer, gastric cancer, multiple myeloma, non-small cell lung cancer and pancreatic cancer.
19. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of an epidermal growth factor receptor (EGFR) antagonist.

20. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of an fms-like tyrosine kinase receptor (flt-1) antagonist.

21. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of a rho associated kinase 2 (ROCK2) antagonist.

22. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of a matrix metalloproteinase antagonist.

23. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of a PDGFR β antibody.

24. The method of any one of claims 16-18, which further comprises administering to a subject an effective amount of a PD-L1 antibody.

25. The method of any one of claims 16-18 wherein the patient is a human.

Fig.1A

Kabat No.		1										2										3										4																																				
		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3																																		
SEQ ID NO.																																																																				
4		E	V	Q	L	L	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	<table><tr><td>G</td><td>F</td><td>T</td><td>F</td><td>S</td><td>W</td><td>Y</td><td>V</td><td>M</td><td>G</td><td>-</td><td>-</td></tr><tr><td>G</td><td>F</td><td>T</td><td>F</td><td>S</td><td>W</td><td>Y</td><td>I</td><td>M</td><td>L</td><td>-</td><td>-</td></tr></table>										G	F	T	F	S	W	Y	V	M	G	-	-	G	F	T	F	S	W	Y	I	M	L	-	-	W	V	R	Q	A	P	G	K
G	F	T	F	S	W	Y	V	M	G	-	-																																																									
G	F	T	F	S	W	Y	I	M	L	-	-																																																									
12		E	V	Q	L	L	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	W	V	R	Q	A	P	G	K																																		

Kabat No.	5										6										7										8																											
	4	5	6	7	8	9	0	1	2	A	B	C	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	A	B	C																							
SEQ ID NO.																																																										
4	G	L	E	W	V	S	S I Y P - - S G G A T N Y A D S V K G																																R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	S	L
12	G	L	E	W	V	S	S I G S - - S G G F T D Y A D S V K G																																R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	S	L

Kabat No.	9										1										0										1									
	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	A	B	C	D	E	F	G	H	I	J	K	L	1	2	3							
SEQ ID NO.																																								
4	R	A	E	D	T	A	V	Y	Y	C	A	R	G N Y F - - - - - D Y										W	G	Q	G	T	L	V	T	V	S	S							
12	R	A	E	D	T	A	V	Y	Y	C	A	R	G L A A P - - - - - R S										W	G	R	G	T	L	V	T	V	S	S							

Kabat No.	1										2										3									
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7			
SEQ ID NO.																														
8	Q	S	V	L	T	Q	D	P	A	-	V	S	V	A	L	G	Q	T	V	R	I	T	C							
24	Q	S	A	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	S	I	T	C							
28	Q	Y	E	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	S	I	T	C							
32	Q	S	V	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	S	I	T	C							
36	Q	S	E	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	S	I	T	C							
40	Q	Y	E	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	T	I	T	C							
44	Q	S	A	L	T	Q	P	P	S	-	V	S	V	S	P	G	H	T	A	T	I	T	C							
48	Q	S	A	L	T	Q	P	P	S	-	V	S	V	S	P	G	Q	T	A	I	I	T	C							
16	Q	S	A	L	T	Q	P	P	S	-	V	S	E	A	P	G	Q	R	V	T	I	S	C							
20	Q	S	A	L	T	Q	P	P	S	-	A	S	G	T	P	G	Q	R	V	T	I	S	C							
52	Q	S	A	L	T	Q	P	P	S	-	V	S	G	T	P	G	Q	R	V	T	I	S	C							
56	Q	Y	E	L	T	Q	P	P	S	-	V	S	E	A	P	G	Q	R	V	T	I	S	C							
60	Q	S	E	L	T	Q	P	P	S	-	A	S	G	T	P	G	Q	R	V	T	I	S	C							
64	Q	S	V	L	T	Q	P	P	S	-	A	S	G	T	P	G	Q	R	V	T	I	S	C							
68	Q	S	E	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
72	Q	S	A	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
76	Q	S	A	L	T	Q	P	P	S	-	M	S	G	S	R	G	Q	S	I	T	I	S	C							
80	Q	S	V	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
84	Q	S	V	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
88	Q	S	V	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
92	Q	S	A	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							
96	Q	S	E	L	T	Q	P	P	S	-	V	S	G	S	P	G	Q	S	I	T	I	S	C							

Fig.1B2

Kabat		4		5		6		7		8																																					
No.		8 9 0		0 1 2 3 4 5 6		7 8 9 0 1 2 3 4 5 6 7 8 9		0 1 2 3 4 5 6 7 8 9		0 1 2 3 4 5 6 7 8 9																																					
SEQ ID NO:																																															
8		Q	K	P	G	Q	S	P	L	V	V	I	Y	Q	D	T	N	R	P	S	G	I	P	E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	I	S	E	T	Q	A	
24		Q	K	P	G	Q	S	P	V	L	V	I	Y	Q	D	N	K	R	P	S	G	I	P	E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
28		Q	R	P	G	Q	S	P	V	L	V	I	Y	Q	D	S	K	R	P	S	G	I	P	E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
32		Q	K	P	G	Q	S	P	V	L	V	I	Y	Q	D	N	K	R	P	S	G	I	P	E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
36		Q	K	P	G	Q	S	P	V	L	V	I	Y	Q	D	N	K	R	P	S	G	I	P	E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
40		H	K	P	G	Q	S	P	I	L	L	I	Y	Q	N	D	K	R	P	S	G	I	P	D	R	F	S	G	S	D	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
44		Q	R	P	G	Q	A	P	V	L	V	L	Y	Q	S	S	Q	R	P	S	G	I	P	E	R	F	S	G	S	I	S	G	N	T	A	T	L	T	I	S	I	S	G	A	Q	S	
48		Q	K	P	G	Q	S	P	V	L	V	I	Y	Q	D	T	K	R	P	S	G	I	P	E	R	F	S	G	S	S	S	G	N	T	A	T	L	T	I	S	I	S	E	T	Q	T	
16		Q	L	P	G	K	A	P	K	L	L	I	Y	Y	D	D	L	L	P	S	G	V	S	D	R	F	S	G	S	K	S	G	T	S	G	S	L	A	I	S	I	S	G	L	Q	S	
20		Q	L	P	G	A	A	P	K	L	L	I	Y	Y	S	T	D	Q	R	P	S	G	V	P	D	R	F	S	G	N	S	G	N	T	A	T	L	T	I	S	I	S	G	T	Q	A	
52		Q	L	P	G	T	A	P	K	L	L	I	Y	Y	A	N	N	Q	R	P	S	G	V	P	D	R	F	S	G	S	R	S	G	T	S	A	S	L	A	I	S	I	S	G	L	Q	S
56		Q	L	P	G	K	A	P	K	L	L	I	Y	Y	Y	D	D	L	L	P	S	G	V	S	D	R	F	S	G	S	K	S	G	T	S	G	S	L	A	I	S	I	S	G	L	Q	S
60		Q	L	P	G	T	A	P	K	L	L	I	Y	Y	T	N	S	Q	R	P	S	G	V	P	D	R	F	S	G	L	Q	S	G	T	S	A	S	L	A	I	S	I	S	G	L	Q	S
64		Q	L	P	G	T	A	P	K	L	L	I	Y	Y	T	N	N	Q	R	P	S	G	V	P	D	R	F	S	G	S	K	S	G	T	S	A	S	L	A	I	S	I	S	G	L	R	S
68		Q	H	P	G	R	A	P	K	F	I	L	Y	Y	D	V	N	N	R	P	S	G	V	A	D	R	F	S	G	F	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
72		Y	H	P	G	K	A	P	K	F	I	L	Y	Y	D	V	N	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
76		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
80		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
84		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
88		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
92		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P
96		H	L	P	G	N	A	P	K	F	I	L	Y	Y	D	V	Y	N	R	P	S	G	V	S	D	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	I	S	G	L	Q	P

Fig.1B3

Kabat		9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3										4										5										6										7										8										9										0										1										2										3									
-------	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--

Kabat		1										2										3													
No.	SEQ ID NO:	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	A	B	C	D	E	F	8	9	0	1	2	3	4	5	6	7	
100		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	S	Y	L	A	W	Y	Q
104		D	I	Q	M	T	Q	S	P	G	T	L	S	V	L	P	G	E	R	A	T	L	S	C		I	S	S	N	Y	L	M	W	Y	Q
108		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		I	S	S	N	Y	L	A	W	Y	Q
112		D	I	Q	M	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	L	S	C		R	S	S	G	Y	L	S	W	F	Q
116		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	N	Y	L	G	W	Y	Q
120		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	N	Y	L	A	W	Y	Q
124		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	N	Y	L	A	W	Y	Q
128		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	W	Y	L	A	W	Y	Q
132		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	G	S	S	Y	L	A	W	Y	Q
136		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	S	Y	L	A	W	Y	Q
140		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	S	Y	L	A	W	Y	Q
144		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	S	Y	L	A	W	Y	Q
148		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	S	Y	L	A	W	Y	Q
152		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	G	A	T	L	S	C		V	S	S	N	Y	F	G	W	Y	Q
156		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	N	Y	L	A	W	Y	Q
160		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	D	R	A	T	L	S	C		V	S	S	N	Y	L	A	W	Y	Q
164		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		L	N	N	N	Y	L	A	W	Y	Q
168		D	I	Q	M	T	Q	S	P	A	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	D	Y	L	A	W	Y	Q
172		D	I	Q	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C		V	S	S	D	Y	L	A	W	Y	Q
176		D	I	Q	M	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C		V	S	S	D	Y	L	A	W	Y	Q
180																																			

Kabat No.	4		5		6		7		8				
	8	9	0	1	2	3	4	5	6	7	8	9	0
SEQ ID NO:													
100	Q	K	P	G	Q	A	P	R	L	L	M	Y	
104	Q	K	P	G	Q	A	P	R	L	L	M	Y	
108	Q	R	P	G	Q	A	P	R	L	L	I	Y	
112	Q	K	P	G	Q	A	P	R	L	L	I	Y	
116	Q	K	P	G	Q	A	P	R	L	L	I	Y	
120	Q	K	P	G	Q	A	P	R	L	L	I	Y	
124	Q	K	P	G	Q	A	P	R	L	L	I	Y	
128	Q	K	P	G	Q	A	P	R	L	L	M	Y	
132	Q	K	P	G	Q	A	P	R	L	L	M	Y	
136	Q	K	P	G	Q	A	P	R	L	L	M	Y	
140	Q	K	P	G	R	A	P	R	L	L	M	Y	
144	Q	K	P	G	Q	A	P	R	L	L	I	Y	
148	Q	K	P	G	Q	A	P	R	L	L	I	Y	
152	Q	K	P	G	Q	A	P	R	L	L	I	Y	
156	Q	K	P	G	Q	A	P	R	L	L	I	Y	
160	Q	K	P	G	Q	A	P	R	V	L	I	Y	
164	Q	K	P	G	Q	A	P	R	L	L	M	Y	
168	Q	K	P	G	R	A	P	R	L	L	M	Y	
172	Q	K	P	G	R	A	P	R	L	L	M	Y	
176	Q	K	P	G	R	A	P	R	L	L	M	Y	
180	Q	K	P	G	R	A	P	R	L	L	M	Y	
184	Q	K	P	G	R	A	P	R	L	L	M	Y	

Fig.1C3

Kabat No.	SEQ ID NO:	9										0										1																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												
100		E	D	F	A	V	Y	Y	C																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						</




Fig. 2




Fig. 3







Fig. 4

A)



B)



C)




Fig. 5

[illegible]

Kabat No.	SEQ ID NO:	9										0										1																		
		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	
160		E	D	S	A	V	Y	Y	C	Q	Q	F	D	S	S	P	L	T	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R
204		E	D	S	A	V	Y	Y	C	Q	Q	F	D	S	L	P	L	T	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R
212		E	D	S	A	V	Y	Y	C	Q	Q	H	D	S	S	P	L	S	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R
220		E	D	S	A	V	Y	Y	C	Q	Q	F	D	S	S	P	L	S	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R
228		E	D	S	A	V	Y	Y	C	Q	Q	F	D	S	S	P	L	T	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R
236		E	D	S	A	V	Y	Y	C	Q	Q	F	D	S	S	P	L	T	F	G	G	G	T	K	V	E	I	K	R	F	G	G	G	T	K	V	E	I	K	R

Fig. 7






Fig. 8

A. Binding to hVEGFR2 on HUVEC and KDR-PAE



B. Binding to mVEGFR2 on MS1 cells






Fig. 10





Fig. 11

A.



B.




Fig. 12

Kabat	1										2										3										4															
No.	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	A	B	6	7	8	9	0	1	2	3	
SEQ ID NO.																																														
4	E	V	Q	L	L	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G F T F S W Y V M G - -										W	V	R	Q	A	P	G	K			
12	E	V	Q	L	L	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S											G	F	T	F	S	W	Y	I	M	L	-

Kabat	5									6										7										8															
No.	4	5	6	7	8	9	0	1	2	A	B	C	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	A	B	C
SEQ ID NO.																																													
4	G	L	E	W	V	S	S I Y P - - S G G A T N Y A D S V K G										R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	S	L									
12	G	L	E	W	V	S											S	I	G	S	-	-	S	G	G	F	T	D	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K

Kabat	9										0										1																								
No.	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	A	B	C	D	E	F	G	H	I	J	K	1	2	3	4	5	6	7	8	9	0	1	2	3			
SEQ ID NO.																																													
4	R	A	E	D	T	A	V	Y	Y	C	A	R	G N Y F - - - - - - - - - - D Y										W	G	Q	G	T	L	V	T	V	S	S												
12	R	A	E	D	T	A	V	Y	Y	C	A	R											G	L	A	A	P	-	-	-	-	-	-	-	-	-	-	-	-	R	S	W	G	R	G

Fig.1A